TY - JOUR
T1 - Engineering of janus-like dendrimers with peptides derived from glycoproteins of herpes simplex virus type 1
T2 - Toward a versatile and novel antiviral platform
AU - Falanga, Annarita
AU - Del Genio, Valentina
AU - Kaufman, Elizabeth A.
AU - Zannella, Carla
AU - Franci, Gianluigi
AU - Weck, Marcus
AU - Galdiero, Stefania
N1 - Funding Information:
Funding: E.A.K. and M.W. thank the National Science Foundation under Grant No. CHE-1902917 for support of this science.
Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2021/6/2
Y1 - 2021/6/2
N2 - Novel antiviral nanotherapeutics, which may inactivate the virus and block it from entering host cells, represent an important challenge to face viral global health emergencies around the world. Using a combination of bioorthogonal copper-catalyzed 1,3-dipolar alkyne/azide cycloaddition (CuAAC) and photoinitiated thiol–ene coupling, monofunctional and bifunctional peptidodendrimer conjugates were obtained. The conjugates are biocompatible and demonstrate no toxicity to cells at biologically relevant concentrations. Furthermore, the orthogonal addition of multiple copies of two different antiviral peptides on the surface of a single dendrimer allowed the resulting biocon-jugates to inhibit Herpes simplex virus type 1 at both the early and the late stages of the infection process. The presented work builds on further improving this attractive design to obtain a new class of therapeutics.
AB - Novel antiviral nanotherapeutics, which may inactivate the virus and block it from entering host cells, represent an important challenge to face viral global health emergencies around the world. Using a combination of bioorthogonal copper-catalyzed 1,3-dipolar alkyne/azide cycloaddition (CuAAC) and photoinitiated thiol–ene coupling, monofunctional and bifunctional peptidodendrimer conjugates were obtained. The conjugates are biocompatible and demonstrate no toxicity to cells at biologically relevant concentrations. Furthermore, the orthogonal addition of multiple copies of two different antiviral peptides on the surface of a single dendrimer allowed the resulting biocon-jugates to inhibit Herpes simplex virus type 1 at both the early and the late stages of the infection process. The presented work builds on further improving this attractive design to obtain a new class of therapeutics.
KW - Antiviral compounds
KW - Dendrimers
KW - Peptides
UR - http://www.scopus.com/inward/record.url?scp=85108008592&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85108008592&partnerID=8YFLogxK
U2 - 10.3390/ijms22126488
DO - 10.3390/ijms22126488
M3 - Article
C2 - 34204295
AN - SCOPUS:85108008592
SN - 1661-6596
VL - 22
JO - International journal of molecular sciences
JF - International journal of molecular sciences
IS - 12
M1 - 6488
ER -